**Supplementary data**

|  |  |  |  |
| --- | --- | --- | --- |
| SUPPLEMENTARY TABLE 1Clinical characteristics vascular | Controls (n=21) | Patients (n=33) | P |
| Sex: male (%) | 10 (47.6) | 17 (50.0) | 1.0 |
| Age (years) | 51.29 (12.99) | 57.47 (11.32) | 0.08 |
| Length (m) | 1.74 (0.087) | 1.74 (0.11) | 0.98 |
| Weight (kg) | 78.2 (64.1-129.8) | 81.95 (58.2-135.3) | 0.22 |
| BMI (kg/m2) | 26.43 (21.43-46.04) | 26.97 (19.96-47.32) | 0.42 |
| Waist-to-hip ratio  | 0.94 (0.7-1.03) | 0.925 (0.77-1.08) | 0.88 |
| Systolic BP (mmHg) | 120.71 (1.59) | 28.94 (16.14) | 0.08 |
| Diastolic BP (mmHg) | 75.14 (8.16) | 80.03 (10.19) | 0.05 |
| Heart rate (/min) | 60 (48-80) | 60 (44-76) | 0.76 |
| Anti-hypertensives (%) | 1 (4.8) | 11 (32.4) | 0.02 |
| Diabetes mellitus (%) | 0 | 3 (8.8) | 0.28 |
| Smoker; current/past (%) | 4/2 (19/9.5) | 5/12 (14.7/35.3) | 0.10 |
| Alcohol use (units/week) | 4 (0-20) | 1.5 (0-21) | 0.17 |
| IGF-1 (nmol/l) | 17.16 (4.59) | 17.57 (4.11) | 0.74 |
| Hormonal deficiency (%)*Estrogen depletion (%)**Hypothyroidism (%)* *Hypogonadism (%)**Hypocortisolism (%)**GH deficiency (%)**Diabetes insipidus (%)**Hyperprolactinemia (%)* | 2 (9.5)5 (45.5)2 (9.5)00000 | 1 (2.9)12 (75)000010 | 0.5510.2240.141 |
| Medical treatment(%)*SSA (%)**Dopamin agonist (%)**Pegvisomant (%)* | 0000 | 15 (44.1)11 (32.4)2 (5.9)2 (5.9) |  |
| Surgery (%) | 0 | 29 (85.3) |  |
| Radiotherapy (%) | 0 | 3 (8.8) |  |
| Cholesterol (*mmol/L)*HDL cholesterol (*mmol/L)*LDL cholesterol (*mmol/L)* Triglycerides (*mmol/L)*Non-HDL cholesterol (*mmol/L)* | 5.37 (1.14)1.53 (1.03-2.84)3.03 (3.13)1.46 (0.58-3.55)3.8 (1.12) | 5.34 (1.13)1.45 (0.77-2.88)3.14 (1.01)0.97 (.66-3.34)3.74 (1.16) | 0.60.890.290.040.98 |

**Supplementary table 1. Clinical characteristics in patients and controls – subgroup selected for vascular measurements.**Values are displayed as mean with SD (standard deviation) or as median with minimum and maximum, depending on the normality of the distribution, which was tested by the Shapiro-Wilk test. Categorical variables are displayed as numbers (percentage); BMI: body mass index in kg/m2; BP: blood pressure; IGF-1: Insulin-like Growth Factor 1; GH: Growth Hormone; Estrogen depletion (in women): postmenopausal women not using estrogen substitution; SSA: Somatostatin analogue; LDL: low-density lipoprotein; HDL: high-density lipoprotein. Differences between two groups were tested with the independent samples Mann-Whitney U test for non-normal data and the independent samples T-test for normal distributed data. Categorical variables were tested using the 2-sided Fisher exact test. P values of <0.05 were considered statistically significant.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| SUPPLEMENTARY TABLE 2Clinical characteristics | Controls (n=21) | Cured (n=19) | Biochemically controlled (n=14) | P | P\* |
| Sex: male (%) | 10 (47.6) | 8 (42.1) | 9 (60) | 0.49 | 0.56 |
| Age (years) | 52 (29-75) | 57 (42-70) | 53 (45-81) | 0.84 | 0.30 |
| Length (m) | 1.74 (0.087) | 1.73 (0.11) | 1.75 (0.12) | 0.65 | 0.88 |
| Weight (kg) | 78.2 (64.1-129.8) | 78.4 (58.2-135.3) | 88 (61.8-109) | 0.23 | 0.22 |
| BMI (kg/m2) | 26.43 (21.43-46.04) | 26.91 (19.96-47.32) | 27.74 (22.98-34.02) | 0.56 | 0.51 |
| Waist-to-hip ratio  | 0.94 (0.7-1.03) | 0.9 (0.77-1.08) | 0.93 (0.87-1.06) | 0.32 | 0.74 |
| Systolic BP (mmHg) | 120.7 (13.59) | 127.7 (18.55) | 130.53 (12.92) | 0.60 | 0.14 |
| Diastolic BP (mmHg) | 75.14 (8.16) | 77.74 (11.86) | 82.93 (6.91) | 0.12 | 0.055 |
| Heart rate (/min) | 60 (48-80) | 60 (44-76) | 64 (56-72) | 0.19 | 0.36 |
| Anti-hypertensives (%) | 1 (4.8) | 6 (31.6) | 5 (33.3) | 1 | 0.02 |
| Diabetes mellitus (%) | 0 | 1 (5.3) | 2 (13.3) | 0.57 | 0.18 |
| Smoker; current/past (%) | 4/2(19/9.5) | 3/8 (15.9/42.1) | 2/4 (13.3/26.7) | 0.72 | 0.19 |
| Alcohol use (units/week) | 4 (0-20) | 3 (0-20) | 0.5 (0-21) | 0.30 | 0.25 |
| IGF-1 (nmol/l)Disease duration (years) | 17.16 (4.59)- | 16.98 (3.9)6 (2-19) | 18.32 (4.37)8.5 (4-35) | 0.36 | 0.350.123 |
| Hormonal deficiency (%)*Estrogen depletion (%)**Hypothyroidism (%)**Hypogonadism (%)**Hypocortisolism (%)**GH deficiency (%)**Diabetes insipidus (%)**Hyperprolactinemia (%)* | 2 (9.5)5 (45.5)2 (9.5)00000 | 1 (5.3)8 (47.1)00001 (5.3)0 | 04 (23.5)000000 | 10.38 | 0.770.640.62 |
| Medical treatment (%)*SSA (%)**Dopamin agonist (%)**Pegvisomant (%)* | 0000 | 0000 | 15 (100)11 (73.3)2 (13.3)2 (13.3) |  | <0.001<0.0010.070.07 |
| Surgery (%) | 0 | 19 (100) | 10 (66.7) |  | <0.001 |
| Radiotherapy (%) | 1 (5.3) | 0 | 2 (13.3) |  | 0.18 |
| Cholesterol (*mmol/L)*HDL cholesterol (*mmol/L)*LDL cholesterol (*mmol/L)*Triglycerides (*mmol/L)*Non-HDL cholesterol (*mmol/L)* | 5.37 (1.14)1.53 (1.03-2.84)3.03 (1.15)1.46 (0.58-3.55)3.80 (1.12) | 5.38 (1.31)1.55 (1.02-2.83)3.16 (1.22)0.86 (0.66-2.77)3.69 (1.4) | 5.28 (0.87)1.45 (0.77-2.88)3.13 (0.65)1.25 (0.69-3.34)3.79 (0.77) | 0.860.490.960.160.81 | 0.830.270.930.210.66 |

**Supplementary table 2. Clinical characteristics in patients and controls – subgroup**

**selected for vascular measurements.**Values are displayed as mean with SD (standard deviation) or as median with minimum and maximum, depending on the normality of the distribution, which was tested by the Shapiro-Wilk test. Categorical variables are displayed as numbers (percentage); BMI: body mass index in kg/m2; BP: blood pressure; IGF-1: Insulin-like Growth Factor 1; GH: Growth Hormone; Estrogen depletion (in women): postmenopausal women not using estrogen substitution; SSA: Somatostatin analogue; LDL: low-density lipoprotein; HDL: high-density lipoprotein. Differences between two groups were tested with the independent samples Mann-Whitney U test for non-normal data and the independent samples T-test for normal distributed data. Categorical variables were tested using the 2-sided Fisher exact test. P values of <0.05 were considered statistically significant.

P\*: P-values when comparing cured patients to patients in biochemical remission.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| SUPPLEMENTARY TABLE 3 | Controls (N=21) | Patients (N=33) | Cured (n=19) | Biochemically controlled (n=14) | P | P\* |
| Central Augmented Pressure (C\_AP\_HR75) (mmHg) | 7.75 (4.03) | 6.68 (6.12) | 7.59 (6.61) | 5.57 (5.5) | 0.04 | 0.019 |
| Pulse wave velocity (m/s) | 9.14 (7.1-15.36) | 8.83 (6.63-13.46) | 9.09 (6.63-13.27) | 8.74 (7.24-13.46) | 0.002 | 0.008 |
| Baseline diameter FMD (cm) | 0.39 (0.09) | 0.43 (0.07) | 0.42 (0.07) | 0.4457 (0.08) | 0.18 | 0.16 |
| Peak diameter FMD (cm) | 0.41 (0.09) | 0.45 (0.07) | 0.44 (0.07) | 0.47 (0.07) | 0.3 | 0.27 |
| Absolute FMD (cm) | 0.03 (0.01-0.07) | 0.02 (-0.01-0.05) | 0.02 (0-0.05) | 0.02 (-0.01-0.04) | 0.27 | 0.39 |
| %FMD | 8.68 (4.87) | 5.22 (3.58) | 5.16 (3.59) | 5.29 (3.73) | 0.06 | 0.15 |
| Shear rate (/min) | 26245 (14287-53297) | 15997 (4676-39954) | 18335 (7320-39954) | 10925 (4676-30588) | 0.002 | 0.07 |
| Blood flow (ml/min)  | 299.15 (50-935) | 304.11 (-3-663) | 323.2 (-3-663) | 302.17 (1-439) | 0.1 | 0.19 |
| Baseline diameter NMD (cm) | 0.38 (0.0766) | 0.43 (0.07) | 0.43 (0.08) | 0.44 (0.05) | 0.17 | 0.37 |
| Peak diameter NMD (cm) | 0.45 (0.07) | 0.52 (0.07) | 0.51 (0.09) | 0.53 (0.04) | 0.02 | 0.06 |
| Absolute NMD (cm) | 0.07 (0.01-0.112) | 0.08 (0.04-0.15) | 0.077 (0.04-0.15) | 0.08 (0.04-0.14) | 0.39 | 0.11 |
| %NMD | 19.8 (2-34.8) | 16.4 (8.4-34.5) | 16.3 (11-34.2) | 16.9 (8.4-34.5) | 0.74 | 0.92 |
| FMD/NMD ratio | 0.42 (0.12-5.95) | 0.27 (-0.08-1.04) | 0.24 (-0.02-1.04) | 0.37 (-0.08-0.88) | 0.04 | 0.13 |
| IMT (mm) | 0.8 (0.17) | 0.83 (0.10) | 0.83 (0.1) | 0.83 (0.11) | 0.48 | 0.76 |
| Lumen (mm) | 6.78 (0.82) | 6.93 (0.79) | 6.76 (0.90) | 7.18 (0.52) | 0.73 | 0.28 |
| IMT / lumen ratio  | 0.12 (0.02) | 0.12 (0.02) | 0.13 (0.02) | 0.12 (0.02) | 0.57 | 0.49 |

**Supplementary table 3. Vascular measurements**Values are displayed as mean with SD (standard deviation) or as median with minimum and maximum, depending on the normality of the distribution, which was tested by the Shapiro-Wilk test. Data were, when necessary, log-transformed prior to analysis. Differences between the subgroups were tested using ANCOVA with *sex* and *systolic blood pressure* as covariates for Augmented Pressure and *age* and *systolic blood pressure* for all other measures. Šidák correction for multiple testing was applied. P values of <0.05 were considered statistically significant. PWV: pulse wave velocity; IMT: intima-media thickness; FMD: flow-mediated dilatation; NMD: nitroglycerine-mediated dilatation.

P: p-values when comparing controls to the total group of patients.

P\*: p-values when comparing controls to subgroups of patients.

****

**Supplementary Figure 1**. LPS-stimulated IL-1β production (A) and LPS-stimulated IL-1Ra production (B) and PHA-stimulated IFN-γ production (C). Cytokine concentrations were measured by ELISA and displayed as mean ± SD. Data were log-transformed prior to analysis. Differences between the subgroups were tested using ANCOVA with BMI, age and leukocyte count as covariates. Šidák correction for multiple testing was applied. P values of <0.05 were considered statistically significant. LPS: lipopolysaccharide; PHA: Phytohemagglutinin; IL: interleukin; IFN-γ: interferon γ.